Rheumatologists using RehumAI reach correct diagnostic and management decisions faster than rheumatologists using standard clinical reasoning alone

Scientific Rationale

What if you have a medical resident by your side, questioning evert answer that you made, but it's not one of your speciality it's from another one, that think different. Complex rheumatology cases require physicians to integrate multisystem symptoms, disease chronology, physical examination findings, biomarkers, imaging, comorbidities, and previous treatment responses, even if those answers anre not published or never shared.

In these cases, the limiting factor is not always a lack of medical knowledge. It may also be how the clinician explores the diagnostic possibility space. Sometimes we could feel frustration and overwhelmed with medical information and even with the full acces for tools we dont know which one to use.

RehumAI proposes a specific hypothesis: a clinical reasoning tool designed to challenge the initial hypothesis, identify discordant evidence, and surface alternative explanations can modify the reasoning pathway through which rheumatologists reach clinical decisions.

The objective is not to replace specialist judgment or demonstrate that AI diagnoses better than rheumatologists. The hypothesis is that Rheumatologist + RehumAI can correctly resolve certain complex cases faster than a rheumatologist working without the tool.

Proposed Mechanism

RehumAI → Broader hypothesis exploration → Identification of overlooked evidence → Hypothesis revision → Faster correct clinical resolution

RehumAI is hypothesized to change the trajectory of clinical reasoning and not only make a verified answer, a very disruptive one.

When evaluating a complex case, the system can surface contradictions, alternative diagnoses, and relationships between findings that may not have been represented in the clinician's initial hypothesis.

This makes the concept of “thinking differently” experimentally measurable rather than simply a product or marketing statement.

Testable Hypothesis

In a prospective controlled study, rheumatologists would be assigned to solve standardized complex clinical cases either with RehumAI or without RehumAI.

The primary endpoint would be:

Time to correct clinical resolution.

Correct resolution should be predefined by an independent expert panel and could incorporate both the appropriate diagnosis and clinical management decision.

Secondary endpoints could include diagnostic accuracy, number and diversity of hypotheses considered, changes from the initial diagnostic hypothesis, diagnostic tests requested, treatment decisions, diagnostic confidence, and concordance with the independent expert panel.

Falsifiability

The claim would be supported if RehumAI produces a statistically and clinically meaningful reduction in time to correct resolution without decreasing diagnostic accuracy or clinical safety.

The hypothesis can also fail.

If rheumatologists using RehumAI do not solve cases faster, demonstrate lower accuracy, or generate potentially unsafe decisions, the claim would not be supported.

This makes the claim a persistent scientific artifact capable of accumulating evidence, replications, critiques, and subsequent refinements.

We can't just give benchmark's as obstacles, we are not playing Go or Chess, we are treating human beings.

Long-Term Quantitative Claim

Once prospective evidence exists, the claim could evolve into a quantitative assertion such as:

“RehumAI reduces median time to correct resolution of complex rheumatology cases by ≥25% without reducing diagnostic accuracy.”

The ≥25% threshold should remain a prospective target rather than a demonstrated result until supported by experimental evidence.